Emcure Pharma receives SEBI nod to float IPO
Emcure Pharmaceuticals, backed by Bain Capital has received approval from Securities and Exchange Board of India's (SEBI) to raise funds through initial public offering (IPO), according to information from the markets regulator. The Company, which filed its preliminary IPO papers with Sebi in December 2023, received observations on June 10, it added.
The Company has established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 Biologics in the Domestic Market & RoW markets & they are the domestic leader in three biologics.
With 350+ brands, five R&D centers and 13 manufacturing facilities established across the country, the Company has strong presence not just in India but also outside India with a wide network across 70+ countries.
Read also: Sanofi India, Emcure Pharma forge exclusive partnership for cardiovascular product distribution
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd